<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(23)</volume><submitter>Fang Z</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Transmembrane p24 trafficking protein (TMED) family members are implicated in several solid tumors, but their clinical relevance for breast cancer (BC) remains unclear. This study aimed to probe their prognostic values and relations with tumor immunity in BC.&lt;h4>Methods&lt;/h4>TMED family mRNA expression was assessed in five microarray datasets (GSE65212, GSE42568, GSE5364, GSE22820 and GSE45827) from Gene Expression Omnibus (GEO) database and invasive breast cancer (BRCA) cohort from The Cancer Genome Atlas (TCGA). Receiver operating characteristic (ROC) curve was performed to determine the predictive values of filtered members of the &lt;i>TMED&lt;/i> family. The protein expressions of screen genes were validated by Clinical Proteomic Tumor Analysis Consortium (CPTAC) data from</pubmed_abstract><journal>Annals of translational medicine</journal><pagination>1280</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9816852</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer.</pubmed_title><pmcid>PMC9816852</pmcid><pubmed_authors>Fang Z</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Song YX</pubmed_authors><pubmed_authors>Tang JH</pubmed_authors><pubmed_authors>Zhou HL</pubmed_authors><pubmed_authors>Yang SY</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Wo GQ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer.</name><description>&lt;h4>Background&lt;/h4>Transmembrane p24 trafficking protein (TMED) family members are implicated in several solid tumors, but their clinical relevance for breast cancer (BC) remains unclear. This study aimed to probe their prognostic values and relations with tumor immunity in BC.&lt;h4>Methods&lt;/h4>TMED family mRNA expression was assessed in five microarray datasets (GSE65212, GSE42568, GSE5364, GSE22820 and GSE45827) from Gene Expression Omnibus (GEO) database and invasive breast cancer (BRCA) cohort from The Cancer Genome Atlas (TCGA). Receiver operating characteristic (ROC) curve was performed to determine the predictive values of filtered members of the &lt;i>TMED&lt;/i> family. The protein expressions of screen genes were validated by Clinical Proteomic Tumor Analysis Consortium (CPTAC) data from</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-07-14T20:25:03.473Z</modification><creation>2024-12-03T15:48:17.912Z</creation></dates><accession>S-EPMC9816852</accession><cross_references><pubmed>36618780</pubmed><doi>10.21037/atm-22-5444</doi></cross_references></HashMap>